60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

Core Viewpoint - 60 Degrees Pharmaceuticals has reported a 100% cure rate for babesiosis in three immunosuppressed patients treated with tafenoquine, suggesting significant potential for this treatment in severe cases of the disease [1][10]. Study Details - The expanded use trial is an open-label, multi-site study assessing the safety and efficacy of the ARAKODA regimen (tafenoquine combined with atovaquone and other treatments) for patients with relapsing babesiosis who have not responded to standard treatments [2]. - Tafenoquine treatment lasts up to one year, requiring two consecutive negative PCR tests for Babesia parasites and resolution of symptoms for a patient to be considered cured [3]. - The study protocol includes follow-up visits to assess parasite infection status using highly sensitive tests, including an FDA-approved RNA amplification test [3]. Previous Research - A Yale study indicated a 100% treatment success rate in four patients when tafenoquine was added to a standard regimen, while a fifth patient did not achieve success due to not sustaining the treatment [4]. - In total, seven patients from both the Yale study and the Company's study showed a near 100% cure rate when tafenoquine was included in their treatment regimen [6]. Implications for Treatment Guidelines - Given the high cure rate associated with tafenoquine, the Company believes it is timely to review existing treatment guidelines for babesiosis [7]. Disease Context - Babesiosis is a serious tick-borne illness that can be life-threatening, particularly in elderly and immunosuppressed patients, with rising incidence rates and no FDA-approved treatments or vaccines currently available [8]. Product Information - Tafenoquine, marketed as ARAKODA, is currently approved for malaria prophylaxis but not for babesiosis treatment [9].